Robles-Nasta M, Lira-Lara O, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Argüelles GJ

Language: Spanish
References: 17
Page: 132-137
PDF size: 216.07 Kb.

ABSTRACT

Introduction: on May 5, 1993, the hematopoietic stem cell transplantation (HSCT) program was started at the Centro de Hematología y Medicina Interna de Puebla in the Clínica Ruiz. As of June 2024, 2,095 HSCT have been conducted. Objective: to analyze the salient features of the HSCT conducted in a private single center in 30 years. Material and methods: the main characteristics of diagnosing persons led to HSCT conducted in the Centro de Hematología y Medicina Interna de Puebla, within the Clínica Ruiz, between 1993 and 2024 were analyzed. Results: 2,095 transplants were done: 1,833 autologous HSCT and 262 allogeneic HSCT. Autologous grafts were done in: multiple sclerosis (79.9%), multiple myeloma (3.7%), acute leukemia (1.6%), chronic leukemia (0.3%) and lymphoma (1.3%). Whereas allogeneic HSCT was conducted in: acute leukemia (6.9%), chronic leukemia (0.7%), bone marrow hypoplasia (0.7%), lymphoma (1.3%), multiple myeloma (0.4%), Diamond-Blackflan anemia (0.04%), non-hematologic neoplasms (0.3%), primary myelofibrosis (0.2%), myelodysplastic syndrome (0.2%), thalassemias (0.1%), PNH (0.1%), and Hunter syndrome (0.04%). Conclusions: with more than 30 years of experience, we have confirmed that both allogeneic and autologous HSCT may be the treatment of choice for some autoimmune diseases and various hematological diseases.

REFERENCES

1. Ruiz-Argüelles GJ. Lessons learned starting a bone marrow transplantation programme in a resource-constrained setting. Lancet Haematol. 2020; 7 (7): e509-e510.

2. León-González M, Núñez-Cortés A, León-Peña A, Torres-Priego M, Zulbarán-Y-Rojas A, Ruiz-Delgado G et al. El programa de trasplantes de células hematopoyéticas de la Clínica Ruiz de Puebla (1993-2016). Rev Hematol Mex. 2016; 17: 205-213.

3. Zamora-Ortiz G, Velázquez-Sánchez-De-Cima S, Hernandez-Reyes J, Vargas-Espinosa J, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Veinte años de experiencia con trasplantes de células hematopoyéticas en la Clínica Ruiz de Puebla, México. Rev Hematol Mex. 2013; 14: 63-70.

4. Ruiz-Delgado GJ, Hernández-Arizpe A, Macías-Gallardo J, Montes-Montiel M, Zamora-Ortiz G, Ruiz-Argüelles GJ. El programa de trasplantes de células hematopoyéticas de la Clínica Ruiz de Puebla (1993-2009). Rev Hematol Mex. 2010; 11: 15-20.

5. Gómez-Almaguer D, Gómez-De León A, Colunga-Pedraza PR, Cantú-Rodríguez OG, Gutierrez-Aguirre CH, Ruíz-Arguelles G. Outpatient allogeneic hematopoietic stem-cell transplantation: a review. Ther Adv Hematol. 2022; 13: 20406207221080739.

6. Rivera-Franco MM, Leon-Rodriguez E, Castro-Saldaña HL. Costs of hematopoietic stem cell transplantation in a developing country. Int J Hematol. 2017; 106 (4): 573-580.

7. Gillis S, Dann EJ, Rund D. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Am J Hematol. 1996; 51 (1): 26-31.

8. Cantú-Rodríguez OG, Jaime-Pérez JC, Gutiérrez-Aguirre CH, González-Llano O, Mancías-Guerra C, Tarín-Arzaga LC et al. Outpatient allografting using non-myeloablative conditioning: the Mexican experience. Bone Marrow Transplant. 2007; 40 (2): 119-123.

9. Murrieta-Álvarez I, Cantero-Fortiz Y, León-Peña AA, Olivares-Gazca JC, Priesca-Marín JM, Ruiz-Delgado GJ et al. The 1,000th Transplant for multiple sclerosis and other autoimmune disorders at the HSCT-México program: a myriad of experiences and knowledge. Front Neurol. 2021; 12: 647425.

10. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010; 303 (16): 1617-1624.

11. Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020; 55 (2): 283-306.

12. Mohammadi R, Aryan A, Omrani MD, Ghaderian SMH, Fazeli Z. Autologous hematopoietic stem cell transplantation (AHSCT): an evolving treatment avenue in multiple sclerosis. Biologics. 2021; 15: 53-59.

13. Al-Anazi KA. Autologous hematopoietic stem cell transplantation for multiple myeloma without cryopreservation. Bone Marrow Res. 2012; 2012: 917361. doi: 10.1155/2012/917361.

14. Naithani R, Dayal N, Pathak S, Rai R. Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma. Bone Marrow Transplant. 2018; 53 (9): 1198-1200.

15. Schroeder T, Fenk R, Saure C, Czibere A, Bruns I, Zohren F et al. The Mexican way: a feasible approach to avoid DMSO toxicity. Bone Marrow Transplant. 2011; 46 (3): 469-471.

16. Sarmiento M, Ramírez P, Parody R, Salas MQ, Beffermann N, Jara V et al. Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy. Bone Marrow Transplant. 2018; 53 (8): 960-966.

17. Saha A, Blazar BR. Antibody based conditioning for allogeneic hematopoietic stem cell transplantation. Front Immunol. 2022; 13: 1031334.